SNUS Sonus Pharmaceuticals (MM)

Sonus Pharmaceuticals, Inc. (NASDAQ:SNUS) today announced that it will release 2006 fourth quarter and year-end financial results on Wednesday, March 14, at the close of market and hold a conference call at 1:30 P.M. PT/4:30 P.M. ET. The year-end conference call will be broadcast live and can be accessed on the Sonus web site at www.sonuspharma.com/events.html. An archive of the call will be available at the same link. A telephone replay of the call will be available from March 14, 4:30 P.M. PT/7:30 P.M. ET, for one week at 800-405-2236 or 303-590-3000 for international calls; Conference ID: 11085952. About Sonus Pharmaceuticals, Inc. Located near Seattle, Washington, Sonus Pharmaceuticals is focused on the development of cancer drugs that are designed to provide better efficacy, safety and tolerability, and are more convenient to use. The Company�s lead product candidate, TOCOSOL Paclitaxel, is currently in a Phase 3 pivotal trial in metastatic breast cancer. TOCOSOL Paclitaxel may have the ability to offer an easier to use and potentially safer and more effective alternative paclitaxel therapy for cancer patients. In addition to the continuing development of TOCOSOL Paclitaxel, Sonus initiated the Phase 1 clinical program for its second cancer drug, TOCOSOL Camptothecin, in September 2006. For additional information on Sonus, including past news releases, please visit www.sonuspharma.com. Safe Harbor Certain statements made in this press release are forward-looking such as those, among others, relating to the development, safety and efficacy of therapeutic drugs and potential applications for these products. As discussed in Sonus Pharmaceuticals' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for 2005 and Quarterly Report on Form 10-Q for the third quarter of 2006, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: the company's products will require extensive clinical testing and approval by regulatory authorities; such approvals are lengthy and expensive and may never occur; risks that the company will not be able to complete the Phase 3 clinical trial for TOCOSOL Paclitaxel; risks that clinical studies with TOCOSOL Paclitaxel will be delayed or will not be successful; risks that the FDA may not approve the TOCOSOL Paclitaxel New Drug Application; risks that the Phase 1 clinical trial for TOCOSOL Camptothecin will not be successful; risks of successful development of therapeutic drugs; and risks that the company may not be successful in obtaining funding from third parties or completing a financing necessary to support the costs and expenses of clinical studies as well as research and development activities. The company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.